This drug-development startup raised about $20 million; now its team builds OpenAI's life-sciences AI; here's what you need to know

Orchestra Bio is a San Francisco-based startup. It was founded by Ashoka Rajendra in 2022. The company's main aim is to develop AI tools to help biotechnology and pharmaceutical companies manage drug development. AI agents are used by its platform...

OpenAI acquires Ashoka Rajendra's Orchestra Bio.

OpenAI acquired Ashoka Rajendra's biotech company Orchestra Bio in October 2026. It was founded in 2022 and is based in San Francisco. The platform was founded by Indian American tech entrepreneur Ashoka Rajendra. The aim was to help biopharma teams coordinate the complex process of drug development. After the development, OpenAI stated, "We're bringing Orchestra’s team and technology together with Rosalind, our AI models and tools for life sciences research." It was claimed that the aim was to help scientists make discoveries. It was also done to manage the work needed to turn them into treatments that reach patients sooner.

The deal meant that it will bring Orchestra Bio's team and technology into OpenAI's life sciences business. They will work alongside Rosalind, its existing suite of AI tools for scientific research.

<blockquote class="twitter-tweet"><p lang="en" dir="ltr">Four years ago to the day, we started Orchestra Bio to help biotech and pharma teams advance their drug development programs. AI has now reached an inflection point where people and agents can take this on together. Today, we’re thrilled to share that Orchestra Bio is joining OpenAI to continue our mission at an even greater scale.</p>— Ashoka Rajendra (@ashokaraj_) <a href="https://x.com/ashokaraj_/status/2112605738120196562?ref_src=twsrc%5Etfw">October 20, 2026</a></blockquote><script async="" src="https://platform.x.com/widgets.js" charset="utf-8"></script>

All about Orchestra Bio

It is a San Francisco-based startup. It was founded by Ashoka Rajendra in 2022. The company's main aim is to develop AI tools to help biotechnology and pharmaceutical companies manage drug development.


AI agents are used by its platforms to track studies, monitor progress and flag problems that could delay a drug programme. The main aim is to reduce the administrative work. It is the kind of work that is involved in developing medicines. Notably, it would allow scientists to focus on research and other key decisions.

ALSO READ: Two former SpaceX engineers built a 25-pound machine that turns seawater into drinking water at the push of a button; here's how it works

Who is Ashoka Rajendra?

Before Orchestra Bio, Ashoka Rajendra worked at Benchling. There he was into product management roles. It also included development and manufacturing.
ADVERTISEMENT

After the deal, Rajendra said, "Developing a new medicine is extraordinarily complex, taking roughly 10 to 15 years on average from target discovery to regulatory approval in the United States. Beyond the science, teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. We’re now at an inflection point where AI can help take on these specialized tasks and complex workflows."
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › International › US News › This drug-development startup raised about $20 million; now its team builds OpenAI's life-sciences AI; here's what you need to know
Text Size:AAA
Success
This article has been saved

*

+